Response to imatinib by CML phase and deletion of der(9) status
. | No. (%) . | . | . | . | ||
|---|---|---|---|---|---|---|
| . | . | Der(9) deletions . | . | . | ||
| Disease stage and cytogenetic response . | Overall . | Yes . | No . | P . | ||
| Chronic phase previously untreated | 151 (100) | 19 (100) | 132 (100) | |||
| Major | 144 (95) | 18 (95) | 126 (95) | > .99 | ||
| Complete | 126 (83) | 18 (95) | 108 (82) | .20 | ||
| Chronic phase after IFN-α failure | 168 (100) | 11 (100) | 157 (100) | |||
| Major | 115 (68) | 8 (73) | 107 (68) | > .99 | ||
| Complete | 93 (55) | 7 (64) | 86 (55) | .75 | ||
| Accelerated phase | 31 (100) | 3 (100) | 28 (100) | |||
| Major | 20 (65) | 2 (67) | 18 (64) | > .99 | ||
| Complete | 17 (55) | 1 (33) | 16 (57) | .57 | ||
. | No. (%) . | . | . | . | ||
|---|---|---|---|---|---|---|
| . | . | Der(9) deletions . | . | . | ||
| Disease stage and cytogenetic response . | Overall . | Yes . | No . | P . | ||
| Chronic phase previously untreated | 151 (100) | 19 (100) | 132 (100) | |||
| Major | 144 (95) | 18 (95) | 126 (95) | > .99 | ||
| Complete | 126 (83) | 18 (95) | 108 (82) | .20 | ||
| Chronic phase after IFN-α failure | 168 (100) | 11 (100) | 157 (100) | |||
| Major | 115 (68) | 8 (73) | 107 (68) | > .99 | ||
| Complete | 93 (55) | 7 (64) | 86 (55) | .75 | ||
| Accelerated phase | 31 (100) | 3 (100) | 28 (100) | |||
| Major | 20 (65) | 2 (67) | 18 (64) | > .99 | ||
| Complete | 17 (55) | 1 (33) | 16 (57) | .57 | ||